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Abstract
Background: Hepatoblastoma (HB) is an embryonal liver neoplasm of early childhood with a poor prognosis for
patients with distant metastases and vascular invasion. We and others have previously shown that the
overexpression of insulin-like growth factor 2 (IGF2), loss of imprinting at the IGF2/H19 locus, and amplification of
pleomorphic adenoma gene 1 (PLAG1) are common features in HB, suggesting a critical role of the IGF axis in
hepatoblastomagenesis. In this study, we investigated the role of the insulin-like growth factor binding protein 3
(IGFBP3), a known competitor of the IGF axis, in pediatric liver cancers.
Results: The IGFBP3 gene was highly expressed in normal pediatric livers but was heavily downregulated in four
HB cell lines and the majority of HB primary tumors (26/36). Detailed methylation analysis of CpG sites in the
IGFBP3 promoter region by bisulfite sequencing revealed a high degree of DNA methylation, which is causatively
associated with the suppression of IGFBP3 in HB cell lines. Consequently, the treatment of HB cell lines with 5-aza-
2’-deoxycytidine resulted in DNA demethylation and reactivation of the epigenetically silenced IGFBP3 expression.
Interestingly, IGFBP3 promoter methylation predominantly occurred in metastatic HB with vascular invasion.
Restoring IGFBP3 expression in HB cells resulted in reduced colony formation, migration, and invasion.
Conclusion: This study provides the first direct evidence that the reactivation of IGFBP3 decreases aggressive
properties of pediatric liver cancer cells and that IGFBP3 promoter methylation might be used as an indicator for
vessel-invasive tumor growth in HB patients.
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Background
Hepatoblastoma (HB) represents the most common pri-
mary liver tumor in childhood with an incidence of
approximately one new case per million children less
than 15 years of age [1]. Pathohistologically, HB resem-
bles various stages of the developing liver, showing
malignant epithelial cells with fetal and/or embryonal
hepatic differentiation and foci of primitive blastemal
cells. The mixed HB subtype also contains interspersed
mesenchymal elements, such as immature fibrous tissue,
spindle cells, and osteoid [1]. Although HB generally
responds well to chemotherapy and the prognosis is
usually good [2], the outcome of high-risk patients with
metastatic tumors or invasion of large hepatic veins is
fatal [3,4].
The type 1 insulin-like growth factor receptor and its
ligands, IGF1 and IGF2, are upregulated in a variety of
human cancers [5]. In pediatric tumors, such as rhabdo-
myosarcoma, nephroblastoma, and HB, the role of the
IGF axis is particularly important [6]. We and others
have shown that the fetal growth factor IGF2 is upregu-
lated in almost all HB cases [7,8], even though the
underlying molecular mechanism is still not understood.
This upregulation could be explained in part by the
observation that the loss of imprinting at the IGF2/H19
locus is evident in approximately 20% of all IGF2
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of the gene [9]. Moreover, the amplification and subse-
quent upregulation of the transcriptional IGF2 activator
PLAG1 has been described in the majority of HB cases
[10]. Collectively, these data suggest that several
mechanisms could be responsible for the frequently
observed upregulation of IGF2, which is characteristic
for the molecular pathogenesis of HB.
The insulin-like growth factor binding protein 3
(IGFBP3) is a multifunctional protein predominantly pro-
duced by the liver, which mediates the growth suppression
and induction of apoptosis by binding insulin-like growth
factors [11]. Accordingly, IGFBP3 transgenic mice exhibit a
significant reduction in both birth weight and litter size,
with a reduction in some organ weights [12]. The stable
transfection of IGFBP3 results in reduced growth rates of
non-small cell lung cancer cells, both in vitro and in vivo,
as xenotransplants in nude mice [13]. Moreover, the addi-
tion of recombinant IGFBP3 results in the massive induc-
tion of apoptosis, as shown in colon and prostate cancer
[14,15]. Conversely, it has been postulated that the suppres-
sion of the putative tumor suppressor gene IGFBP3 could
lead to elevated levels of insulin-like growth factors, thus
promoting tumor growth. Because mutational inactivation
has been precluded as being causative for IGFBP3 suppres-
sion [16], epigenetic inactivation by promoter methylation
has recently been considered as an alternative mechanism
[17,18]. It is a well-described phenomenon that the sup-
pression of tumor suppressor genes could be facilitated by
abnormal methylation of DNA at certain CpG islands that
often lie in the promoter regions of these genes [19].
Because the activation of IGF signaling is characteris-
tic for HB and IGFBP3 suppression contributes to the
sustainment of IGF signaling, we wanted to determine
t h er o l eo ft h eIGFBP3 gene in the biology of pediatric
liver cancers. We demonstrate that the downregulation
of IGFBP3 expression is a common feature in HB,
which is associated with CpG island promoter methyla-
tion in advanced, high-risk HB cases. In addition, we
reveal that IGFBP3 is epigenetically silenced in HB cell
lines and that the reintroduction of IGFBP3 leads to the
inhibition of tumor cell migration and invasion. These
findings indicate that the suppression of IGFBP3 dis-
plays an alternative mechanism for enhancing IGF sig-
naling in the late stages of HB development.
Results
Downregulation of IGFBP3 is a common event in pediatric
liver tumors
To define the IGF signaling status in our pediatric liver
tumor collection, we initially investigated the endogen-
ous expression of the ligand IGF2 and its positive regu-
lator PLAG1. Real-time PCR analysis revealed that the
mRNA level of IGF2 was markedly increased (> 3-fold
induction compared to normal livers) in 23/36 (64%) of
HB and 3/9 (33%) of hepatocellular carcinoma (HCC)
cases (Figure 1A). Furthermore, we detected a strong
upregulation of PLAG1 in 20/36 (56%) of HB and 1/9
(11%) of HCC tumors (Figure 1B). Interestingly, a high
IGF2 expression correlated well with PLAG1 upregula-
tion, predominantly in HB cases (Figure 1C).
Because IGFBP3 has been described to act as a nega-
tive regulator of the IGF axis by competitively binding
IGFs [11], we were interested in whether the downregu-
lation of this gene could also contribute to the activation
of IGF signaling in HB. By using real-time PCR, we
demonstrate that IGFBP3 mRNA levels are heavily
decreased (> 3-fold reduction compared to normal
livers) in 26/36 (72%) of HB cases (Figure 1D). As pre-
viously described for HCC in adults [17], we also
detected a reduced IGFBP3 expression in 6/9 (67%) of
pediatric HCC cases (Figure 1D) compared to normal
childhood liver tissues. IGFBP3 has recently been
described to be transcriptionally downregulated by bind-
ing T-cell-restricted intracellular antigen-1 (TIA1),
which is also overexpressed in human HCC [20]. Corre-
spondingly, TIA1 is also upregulated in the majority of
HB cases (Figure 1E) and is inversely correlated with the
expression of IGFBP3 (Figure 1F), although at a low
level (rho = -0.3295) Altogether, these data suggest that
the downregulation of IGFBP3 might significantly con-
tribute to the activation of the IGF signaling cascade by
sustaining the IGF2-induced stimulation in HB.
Promoter methylation causes IGFBP3 silencing in human
HB cell lines
Promoter methylation has been described as a molecular
mechanism to suppress the gene expression of negative
regulators of tumor growth in a variety of cancers [19].
Because TIA1 upregulation does not completely explain
the suppression of IGFBP3 in pediatric liver tumors (Fig-
ure 1F), we examined a CpG island located in the IGFBP3
promoter region for differential methylation in established
HB cell lines, namely HUH6, HepT3, HepT1, and HepG2,
and the non-hepatitis B virus-associated HCC cell line
HUH7, as well as normal liver by means of bisulfite
sequencing. We found that the entire IGFBP3 promoter
region was heavily methylated in all four HB cell lines and
heterogeneously methylated in HUH7, whereas the normal
liver DNA was rarely methylated in this region (Figure
2A). Interestingly, promoter methylation was well corre-
lated with very low IGFBP3 expression levels in HB cell
lines and a detectable expression in HUH7 when com-
pared to a normal liver, as revealed by real-time and RT-
PCR (Figure 2B). Because promoter methylation has a
strong impact on the transcriptional activity, we next
wanted to determine whether treatment with the
demethylating agent 5-Aza-dC could revert the
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establish IGFBP3 expression in these cell lines. After the
5-day 5-Aza-dC treatment and subsequent MSP analysis,
we detected an increasing amount of demethylation in the
IGFBP3 promoter, thereby qualifying MSP as an appropri-
ate means to analyze DNA methylation (Figure 2C). Bisul-
fite sequencing of single clones of 5-Aza-dC-treated
HepG2 and HUH6 cells revealed a decreased methylation
rate of 12.2% and 12.0%, respectively (data not shown).
Interestingly, 5-Aza-dC treatment significantly re-estab-
lished IGFBP3 expression in all cell lines (Figure 2D),
which was most prominent in the HepT1 and HepG2
cells. These data suggest that promoter hypermethylation
is causatively associated with transcriptional silencing of
the IGFBP3 gene in pediatric liver tumors.
The histone-deacetylase inhibitor trichostatin A has
formerly been described to display strong effects on the
transcriptional regulation of IGFBP3 [21]. Treatment of
all five liver cancer cell lines with trichostatin A resulted
in the strong demethylation (Figure 2C) and reexpres-
sion (data not shown) of IGFBP3, comparable to the
effect communicated by 5-Aza-dC but in a much
shorter period (24 h). Thus, it might be expected that
both promoter methylation and histone-deacetylation
may play important roles in the control of the IGFBP3
tumor suppressor in the liver.
IGFBP3 promoter methylation predominantly occurs in
metastatic high-risk liver tumors with large vessel
invasion
To assess whether IGFBP3 promoter methylation is
clinically relevant, we performed a methylation analysis
of our pediatric liver tumor collection using MSP.
IGFBP3 methylation was detected in 9/36 (25%) of HB
and 6/9 (66%) of pediatric HCC cases, whereas normal
liver tissues had no bands for the methylated state
(Figure 3A, B). However, there was no clear correlation
between IGFBP3 promoter methylation and reduced
IGFBP3 expression levels (data not shown). By analyz-
ing clinicopathological features, such as gender, age at
diagnosis, tumor differentiation, metastatic disease,
outcome, multifocality, and vascular invasion (Table 1),
we observed that IGFBP3 promoter methylation was
significantly associated with metastases and invasion
into large hepatic veins, two high-risk parameters for
HB patients. Moreover, the overall survival of patients
with IGFBP3 methylation was strongly reduced (Figure
3C). These data suggest that aberrant CpG island
methylation of the IGFBP3 promoter region is a late
event in the genesis of pediatric liver tumors and
might predict the evolution of HB to a highly aggres-
sive, metastatic, and vascular-invasive phenotype with
worse outcomes.
Figure 1 Expression analyses of pediatric liver cancers by real-time PCR.T h er e l a t i v eIGF2 (A) PLAG1 (B), IGFBP3 (D),a n dTIA1 (E) mRNA
expression levels of the 45 pediatric liver tumor cases and 7 normal liver samples were determined. The dots represent relative candidate gene
expression in relation to the house-keeping gene TBP. Data from the HB and pediatric HCC cases are depicted as black and orange diamonds,
respectively. Median expression values are given as red horizontal lines. Correlation analyses of pediatric liver cancers. The mRNA expression
levels of IGF2 (C) and IGFBP3 (F) were correlated with PLAG1 and TIA1, respectively. Dots represent log2 values of the relative expression of
candidate genes blotted versus each other in the 45 pediatric liver tumor samples (rho = Spearman’s rank correlation coefficient).
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and apoptosis in HB
IGFBP3 is thought to mediate growth suppression and
induce apoptosis by binding IGFs [11]. Thus, we deter-
mined whether the reintroduction of IGFBP3 into liver
tumor cells could change the tumor’s biological proper-
ties. Adding 1 μg/ml recombinant human IGFBP3 to
tumor cell lines resulted in comparable growth rates
over time (Figure 4A). In line with this, IGFBP3-substi-
tuted cells displayed no significant increase in apoptotic
characteristics, such as elevated external appearance of
phosphatidylserine (Figure 4B) or proteolytic cleavage of
the PARP protein (Figure 4C). In order to see long-term
effects, we used HepT1 cells stably transfected with an
IGFBP3 expression plasmid that resulted in highly ele-
vated IGFBP3 mRNA and protein levels (Figure 4D).
Although stable transfectants displayed no reduction in
growth within 96 h (Figure 4E), we found a significantly
reduced clonogenic survival rate after 2 weeks, as evi-
denced by the lower number of colonies (Figure 4F).
Furthermore, IGFBP3-transfected cells showed signs of
apoptosis, such as cell shrinkage, membrane blebbing,
and formation of apoptotic bodies, when compared to
control-transfected cells (not shown) and an increase in
the external appearance of phosphatidylserine (Figure
4G). Taken together, our results document that long-
term reconstitution of IGFBP3 acts as a tumor suppres-
sive factor in pediatric liver tumors.
Recombinant IGFBP3 slows the migratory and invasive
capacity of liver tumor cells
As IGFBP3 has been described to suppress migration
and invasion in several cancers [22,23], we desired to
determine whether the restoration of IGFBP3 function
Figure 2 (A) Methylation status of the IGFBP3 promoter in HB cell lines. Bisulfite sequencing of the 5’ region of IGFBP3 was performed in
the indicated liver tumor cell lines and normal liver (NL) tissue. The open and filled circles represent unmethylated and methylated CpG sites,
respectively. The location of each CpG site relative to the transcription start site (in base pairs) and the region used for MSP analysis, including
the forward (F) and reverse (R) primer, is shown below. (B) mRNA level of IGFBP3 in HB cell lines. Expression of IGFBP3 was measured in
normal liver tissue (NL) and in the liver tumor cell lines HepG2, HepT1, HepT3, HUH6, and HUH7 by real-time and RT-PCR. The values represent
the relative gene expression in relation to the house-keeping gene TBP. (C) Demethylation of the IGFBP3 promoter region after 5-Aza-dC or
trichostatin A treatment. Cells were incubated for 5 days with 5-Aza-dC and 24 hours with trichostatin A. Methylation status (U, unmethylated;
M, methylated) of the IGFBP3 promoter region was determined using MSP. Representative images of the MSP experiments are given. (D)
Restoration of IGFBP3 expression. The reactivation of IGFBP3 expression after 5 days of 5-Aza-dC treatment in HB cell lines, as revealed by real-
time PCR. Statistically significant difference versus untreated cells: *P < 0.05 (unpaired Student’s t-test).
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of liver tumor cells. Using wound healing assays, we
demonstrated that HepT1 cells stably transfected with
IGFBP3 had a markedly slower cell migration into a
cell-free wound within 48 h than their control trans-
fected counterparts (Figure 5A). By choosing liver tumor
cell lines with high migration rates, namely HepG2 and
HUH7, migration assays using collagen-coated transwell
inserts demonstrated a significantly decreased migration
of tumor cells incubated with recombinant human
IGFBP3 (Figure 5B). Moreover, tumor cells lost their
invasiveness when recombinant human IGFBP3 was
added to the culture medium, as evidenced by the trans-
well assays with Matrigel coated inserts (Figure 5C).
Altogether, these data clearly indicate that restoring
IGFBP3 function could dramatically diminish the migra-
tory and invasive properties of liver tumor cells.
Discussion
Binding of the IGF2 ligand and the subsequent activa-
tion of the IGF1 receptor is known to confer a survival
advantage for a wide range of cell types [24]. Conse-
quently, constitutive activation of the IGF axis is a com-
mon feature of tumor cells, especially those of early
childhood cancers [6,25]. The prevailing mechanism for
IGF pathway activation in HB has been allocated to the
overexpression of IGF2, which is a result of genetic and
epigenetic alterations at the PLAG1 and IGF2/H19 locus
[7,8,10,26] and causes activation of the downstream ser-
ine/threonine kinase and survival factor AKT [27]. The
present study adds an alternative activation mechanism,
namely the augmentation of the IGF/IGF1R interaction
through downregulation of the IGF2 competitor
IGFBP3. We provide evidence that low IGFBP3 expres-
s i o ni sac o m m o np h e n o m e n o ni nH Bt h a tm a yc o n t r i -
bute to the activation of the IGF axis at the
physiological level by the loss of ligand sequestration.
Furthermore, the loss of IGFBP3 expression could be
attributed to the methylation of the IGFBP3 promoter
in at least some primary HB cases, with a predominant
occurrence of this epigenetic alteration in metastatic
and vascular-invasive high-risk tumors. Our data sup-
port the hypothesis that IGFBP3 silencing may contri-
bute to enhanced IGF2/IGF1R signaling and thus the
survival and progression of transformed liver cells at a
late stage of the disease, which may eventually have con-
siderable clinical implications.
One interesting finding of the current study is that
promoter hypermethylation is one possible mechanism
for IGFBP3 silencing in HB. We unequivocally demon-
strated that DNA is heavily methylated throughout the
entire IGFBP3 promoter region of all four HB cell lines
under investigation, which conveys a strong suppression
of IGFBP3 transcription. These repressive modifications
could be removed by the addition of the demethylating
agent 5-Aza-dC to the cycling cells, thereby re-establish-
ing IGFBP3 expression. Aberrant DNA methylation has
been shown to play an important role in the silencing of
IGFBP3 expression in several human cancers, including
gastric, colorectal, breast [18], ovarian [28], and renal
cancer [29], as well as HCC in adults [17]. However,
because DNA methylation only explains the downregu-
lation of IGFBP3 in a subset of primary HB cases, mole-
cular mechanisms other than DNA methylation might
also be responsible for the low IGFBP3 expression levels
found in the majority of primary HB tumors. Degrada-
tion of IGFBP3 by cathepsin D, a specific protease of
IGFBP3, has been envisaged as an alternative suppres-
sion mechanism of IGFBP3, at least at the protein level
[17]. Upregulation of the regulatory protein TIA1 that
binds to the AU-rich region of the 3’-UTR of IGFBP3
Figure 3 (A) Methylation status of the IGFBP3 promoter in
pediatric liver cancers. Summary of the analyses of the IGFBP3
methylation status in the 36 hepatoblastomas (HB), 9 pediatric
hepatocellular carcinomas (HCC), and 7 normal pediatric liver
samples (NL), as determined by MSP. The black boxes represent the
detection of methylated alleles, and the white boxes depict
unmethylated alleles. (B) Methylation-specific PCR (MSP) of
pediatric liver cancers. The promoter region of the IGFBP3 gene
was analyzed for methylated CpG sites by MSP using bisulfite-
treated genomic DNA from pediatric liver tumors (T) and normal
liver tissue (N). Representative images of the MSP experiments are
shown, revealing PCR products for unmethylated (U) and
methylated alleles (M). In vitro methylated DNA (SssI) was used as a
positive control for methylated alleles. (C) Overall survival (OS)
stratified by methylation status. OS was calculated as the time
from diagnosis to death from disease and is plotted for 8 HB
patients with (orange line) and 25 without (black line) IGFBP3
promoter methylation over a period of 100 months. Statistical
significance was calculated using Mantel-Cox test.
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regulation of IGFBP3 in primary HCC [20]. As we have
detected an inverse correlation of TIA1 and IGFBP3,i t
could be assumed that this suppressive mechanism
could act in pediatric liver tumors. In addition, histone
deacetylation may also play an important role in the
suppression of IGFBP3, as shown in this and other stu-
dies [21]. Nevertheless, technical restrictions, such as
heterogeneity of tumor samples, which comprise the
stromal components and the adjacent normal liver tissue
in low proportions, might have contributed to an under-
estimation of HB cases with a methylated IGFBP3 pro-
moter in our study. Noteworthy, a discrepancy between
high methylation rates in tumor cell lines and relative
low rates in primary tumors is a common phenomenon
[30-32]. It has been suggested that a large proportion of
CpG hypermethylation found in cancer cell lines reflects
an intrinsic property of mammalian cells grown in cul-
ture rather than a dependency on the cell of origin.
Furthermore, the accumulation of epigenetic changes
during the prolonged culture of human embryonal stem
cell lines and their derivatives has been described [33].
Alternatively, it might be sp e c u l a t e dt h a ts u b c l o n e s
within primary cancers with aberrant CpG island methy-
lation may be preferentially selected during cell passage
and/or that cancers with high levels of aberrant CpG
methylation could be more likely to become established
as cell lines. Nevertheless, our functional data clearly
show that IGFBP3 silencingi sn o tj u s tac e l lc u l t u r e
artifact, but instead, it plays an important role in driving
adverse growth characteristics of liver cancer cells
originating from advanced stages of liver tumor
development.
In addition to its mechanistic role in gene silencing,
IGFBP3 promoter methylation might also have clinical
implications as a biomarker. It has been reported that
IGFBP3 is frequently methylated and significantly asso-
ciated with a poor prognosis in early-stage non-small-
cell lung [34,35], ovarian [28], and prostate cancer [36].
In contrast to these studies, in which hypermethylation
of the IGFBP3 promoter is a common and early event
during tumorigenesis, we found only 9/36 of HB tumor
cases to be methylated, seven of which were high-risk
metastatic tumors, indicating a late event in the devel-
opment of HB. Moreover, as IGFBP3 promoter methyla-
tion was significantly associated with vascular invasion
in HB and occurred more frequently in pediatric HCC,
the detection of this epigenetic alteration might be used
as an attractive biomarker for stratifying patients for
risk-adapted therapy. Congruent with our assumption,
high promoter hypermethylation frequencies of tumor
suppressor genes, including IGFBP3, already serve as an
indicator for a distinct subclass of advanced HCC in
adults with a poor prognosis [37]. This relationship, in
turn, suggests that demethylating drugs, which have
already been under clinical evaluation [38], might be a
novel therapeutic option to treat high-risk liver tumor
patients. However, further studies in a large cohort of
HB patients are warranted.
Our finding that IGFBP3 restoration results in
reduced tumor cell migration and invasion, while leaving
growth and apoptosis merely unaffected, also
Table 1 Associations of the clinical characteristics and IGFBP3 methylation status in 36 pediatric patients with
hepatoblastoma
IGFBP3
parameters group no. of tumors methylated unmethylated P
gender
a m 18 3 15 0.2482
f1 8 6 1 2
age at diagnosis
b < 2 21 4 17 0.3570
>2 1 2 4 8
histological subtype
c f 20 3 17 0.1213
e1 6 6 1 0
metastases yes 15 7 8 0.0047
no 19 1 18
outcome
d NED 25 4 21 0.0508
DOD 8 4 4
multifocal growth yes 7 3 4 0.2662
no 19 4 15
invasion of large hepatic veins yes 8 6 2 0.0001
no 25 2 23
am, male; f, female
bThe age of patients at diagnosis is given in months
cEpithelial component with predominantly fetal, f, or embryonal, e, differentiation
dNED, no evidence of disease; DOD, dead of disease
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Page 6 of 11Figure 4 (A) Growth properties of IGFBP3 treated HB cells. The viability of tumor cells in the presence (IGFBP3) or absence (control) of 1 μg/
ml recombinant human IGFBP3 was assessed at the time points indicated using MTT assays and optical density (OD) measurements. The values
given represent the mean ratio of treated versus untreated cells from triplicate measurements ± SEM. (B) Annexin V staining. IGFBP3-treated
cells were analyzed for phosphatidylserine membrane asymmetry using Cy5-conjugated annexin V and calcein staining. Representative plots of
the flow-cytometric measurements depicting the percentages of apoptotic cells (annexin V and calcein positive) in the control (left panel) and
recombinant human IGFBP3 treated cells (right panel) are shown. (C) Proteolytic cleavage of PARP. Activation of PARP by proteolytic cleavage
was measured in tumor cells treated with or without recombinant human IGFBP3 by Western blot analysis using antibodies for cleaved PARP
and b-actin as a loading control. (D) Stable IGFBP3 transfectants. HepT1 cells were transfected with an empty vector control (pIRES) or
expression vector containing full-length IGFBP3 cDNA (pIGFBP3), selected with puromycin for 2 weeks and cloned by picking resistant colonies.
Exogenous IGFBP3 expression was measured in transfected HepT1 cells using real-time PCR in relation to the house-keeping gene TBP as a
calibrator (left) or Western blot analysis using antibodies for IGFBP3 and b-actin as a loading control (right). (E) Growth properties of IGFBP3
transfected HepT1 cells. The viability of stably transfected cells was assessed at the time points indicated using MTT assays and optical density
(OD) measurements. The values given represent the mean of triplicate measurements ± SEM. (F) Colony formation assay. HepT1 cells were
transfected with an empty vector control (pIRES) or IGFBP3 expression vector (pIGFBP3) and subsequently cultured in puromycin-containing
media for 2 weeks. Colonies were stained with crystal violet, and representative assays were photographed (left) and counted (right).
Statistically significant difference versus control: *P < 0.05 (unpaired Student’s t-test). (G) Annexin V staining. IGFBP3 transfected cells were
analyzed for phosphatidylserine membrane asymmetry using Cy5-conjugated annexin V and calcein staining. Representative plots of flow-
cytometric measurements depicting 2.4% and 10.6% of apoptotic cells (annexin V and calcein positive) in the control (upper plot) and IGFBP3
transfectants (lower plot) are shown (left). The mean percentages of early apoptotic cells ± SEM of two independent annexin V experiments are
given (right). Statistically significant difference versus vehicle: *P < 0.05 (unpaired Student’s t-test).
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advanced stages of liver tumor development in children.
Furthermore, IGFBP3 has been shown to suppress
migration and invasion in adult HCC [22] and mela-
noma [23]. Interestingly, low IGFBP3 levels have been
found to correlate with higher portal invasion and worse
prognosis in HCC [39]. Altogether, these data suggest
that IGFBP3 downregulation likely has a major role in
the vascular invasive and metastatic growth properties
of pediatric liver tumors.
Conclusions
In summary, our study clearly documents the following
regarding IGFBP3: i) it is downregulated in a high pro-
portion of pediatric liver tumors; ii) it is epigenetically
silenced in a subset of HB, indicating that additional
repressive mechanisms must exist for this gene; iii) pro-
moter methylation is a late event and predominantly
occurs in progressed metastatic and vessel-invasive HB,
which may be of clinical significance for HB patients by
proposing adapted therapies; and iv) it prevents the
migration and invasiveness of HB. Thus, it is intriguing
to speculate that restoring IGFBP3 expression and/or
use of demethylating drugs could contribute to new
therapeutic strategies for HB, especially with the exis-
tence of additional epigenetically silenced genes in this
tumor type, such as HHIP, RASSF1, SOCS1, APC and
CASP8 [40].
Methods
Subjects and tumor cell lines
A total of 45 liver tumor specimens were obtained from
pediatric patients undergoing surgical resection in our
clinic. Normal liver matching was available from seven
patients (N146, N175, N198, N227, N253, N254, and
N629). Written informed consent was obtained from
each patient, and the study protocol was approved by
the Committee of Ethics of the Ludwig-Maximilians-
University of Munich. We used the HB cell lines HUH6
(Japanese Collection of Research Bioresources, JCRB,
Osaka, Japan), HepT1 [41], HepT3 [7], and HepG2 [42],
as well as the hepatocellular carcinoma (HCC) cell line
HUH7 (JCRB). All cell lines were maintained as the sup-
pliers recommended.
Real-time reverse transcription-PCR (RT-PCR)
The total RNA was extracted from macroscopically
dissected frozen tumor tissue (at least 80% tumor
cells), frozen normal liver tissue and HB cell lines,
depleted from residual DNA, and reverse transcribed
as previously described [43]. PCR amplifications were
c a r r i e do u tw i t h4 0n go fc D N A ,5 0 0n Mf o r w a r da n d
reverse primers and iTaq SYBR Green Supermix (Bio-
Rad Laboratories, Hercules, CA, USA) on a
Figure 5 (A) Scratch assay. Representative images of HepT1 cells
stably transfected with empty vector control (pIRES) or IGFBP3
migrating into a cell-free wound at 0, 24, and 48 h after wound
infliction. Quantitative evaluation of wound closure shows the mean
values of three independent experiments. (B) Cell migration and
(C) invasion assays. Representative images of HepG2 and HUH7
cells migrating through collagen- (B) or Matrigel-coated (C)
transwell plates (pore size, 8 μm) in the presence (IGFBP3) or
absence (control) of 1 μg/ml recombinant human IGFBP3. 10% FCS
and 50 ng/ml recombinant human HGF served as a
chemoattractant in the lower compartment (IGFBP3 and control),
whereas a negative control was run without a chemoattractant. The
data are the mean ± SEM from three individual experiments. An
asterisk indicates P < 0.05.
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2 cycler (Eppendorf, Hamburg,
Germany) with 40 cycles consisting of a 15 sec dena-
turation at 95°C, primer annealing for 15 sec at 55°C,
and extension for 30 sec at 72°C. We used the follow-
ing primer pairs (5’->3 ’ orientation): IGF2,
CCTCCGACCGTGCTTCC, GGTGGACTGCTTC-
CAGGTGT; PLAG1, ACAAGTGCATACAACAA-
GACTGCA, CAGGAGAATGAGTAGCCATGTGC;
IGFBP3, GTCCAAGCGGGAGACAGAATAT,
CCTGGGACTCAGCACATTGA; TIA1,T T A G C C A -
GATTGGACCTTGTAAAAA, CGATGCTCAT-
GAAACTCCACA; TBP, GCCCGAAACGCCGAATAT,
CCGTGGTTCGTGGCTCTCT. Amplification of the
house-keeping gene TATA-Box-binding-Protein (TBP)
was performed to standardize the amount of sample
RNA according to a previous study [44]. PCR efficien-
cies for all assays were determined, with slopes ranging
from -3.34 to -3.69. The relative quantization of gene
expression was performed using the ΔΔct method as
previously described [45].
Methylation analyses
Genomic DNA from frozen tumor and normal liver
samples (see above) and cell lines was extracted with
phenol and chloroform, precipitated with ethanol and
dissolved in TE buffer following standard procedures.
Genomic DNA (10 μg) from a healthy person was
methylated in vitro using 40 U CpG methyltransferase
(SssI), S-adenosylmethionine, and NEBuffer2 (New Eng-
land Biolabs, Frankfurt, Germany) at 37°C for 4 h, preci-
pitated with ethanol, dissolved in TE buffer, and used as
a positive control for methylated alleles. Genomic DNA
(2 μg) was bisulfite-treated using the EpiTect
® Bisulfite
Kit (Qiagen, Hilden, Germany) and amplified using pri-
mers not specific for methylation status (IGFBP3-BS-F,
GGTGTTGAGTTGGTTAGGAGT; IGFBP3-BS-R,
AAACAACACCAACAAAATCAA). We cloned the PCR
products into the pCR2.1 TOPO vector (Invitrogen,
Karlsruhe, Germany) and sequenced six independent
clones per sample (MWG Biotech, Ebersberg, Germany).
In addition, the methylation status of the promoter
region of IGFBP3 (from -314 to -147 bp upstream of
transcriptional start site) gene was analyzed by methyla-
tion-specific-PCR (MSP) using the following primer sets
5’->3 ’ orientation): methylated (IGFBP3-M-F,
TGATTCGGGTTTCGGGCGTGC; IGFBP3-M-R,
GCCGACCGCTATATAAAAACCG) and unmethylated
(IGFBP3-U-F, GGTGATTTGGGTTTTGGGTGTGTG-
TAT; IGFBP3-U-R, AAACACACCAACCACTATA-
TAAAAACCAAA). MSP primer design and PCR
conditions were performed according to [43]. For DNA
demethylation experiments, we used 0.5 μM5 - a z a - 2 ’-
deoxycytidine (5-Aza-dC; Sigma-Aldrich, Seelze, Ger-
m a n y )f o rH U H 6a n dH e p T 3c e l l sa n d1 . 2 5μMf o r
HepT1, HepG2 and HUH7 cells; 5-the Aza-dC was
applied for 5 days and changed daily. Alternatively, Tri-
chostatin A (Sigma-Aldrich) was applied for 24 h in a
concentration of 0.1 μM (HUH6 and HepT3) and 0.25
μM (HepT1, HepG2 and HUH7).
Stable transfection
HepT1 cells (5 × 10
5 cells/6-well plate) were transfected
with 1 μg DNA of the pIRES-IGFBP3 expression vector
containing full-length IGFBP3 cDNA [46] or the empty
vector control using the FuGene 6 transfection reagent
(Roche Diagnostics, Mannheim, Germany). After 24 h of
transfection, the cells were changed to media containing
1 μg/ml puromycin (Sigma-Aldrich). After 2 weeks of
selection, puromycin-resistant colonies were selected
and cultured as stable transfected HepT1 clones. Wes-
tern blot analysis was performed using rabbit polyclonal
anti-IGFBP3 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and rabbit anti-human b-actin (Cell Signaling,
Technology, Danvers, MA, USA) antibodies, as pre-
viously described [43].
Cell viability assay
For the proliferation assay, 5 × 10
3 cells were seeded
into 96-well plates, and the viability was assessed at the
time points indicated using the Cell Proliferation Kit I
(Roche Diagnostics) according to the manufacue’s proto-
col. The optical density wasm e a s u r e da taw a v e l e n g t h
of 595 nm after the addition of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) labeling
reagent on the GENios microplate reader (Tecan, Män-
nedorf, Switzerland).
Colony formation assay
HepT1 cells (5 × 10
5 cells/well) were transfected in a 6-
well plate format with 1 μgo ft h ep I R E S - I G F B P 3
expression vector or control vector using the FuGene 6
transfection reagent (Roche Diagnostics). They were
subsequently cultured in selection media containing 1
μg/ml puromycin (Sigma-Aldrich) for 2 weeks. Colonies
were fixed with 100% methanol, stained with 0.1% crys-
tal violet and counted.
Apoptosis analyses
For annexin V-based apoptosis analysis, cells were tryp-
sinized, washed with PBS, and suspended in 500 μlo f
calcium-containing binding buffer. Cy5-conjugated
annexin V (1:100; BioVision, Mountain View, CA, USA)
and 5 μM calcein (Invitrogen) were added to the cell
suspension. Early apoptotic cells (annexin V and calcein
positive) were detected using cell fluorescence assays
with an Agilent 2100 Bioanalyzer. The cleavage of poly
(ADP-ribose) polymerase was detected as previously
described [47] using antibodies for human poly(ADP-
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Signaling Technology, Danvers, MA, USA).
Cell migration assay
HB cells were seeded into 24-well plates and grown to
confluency. A wound of approximately 1 mm was
inflicted to cell monolayers with a pipette-tip. The wells
were washed twice with PBS to remove detached cells
and incubated at 37°C with medium in the presence or
absence of 1 μg/ml recombinant human IGFBP3 (R&D
systems, Wiesbaden, Germany) for 72 h. Images were
taken at 0, 24, and 48 h after scratching, and the wound
widths were measured and quantified.
Transwell assays
Transwell permeable supports (8 μm pore polycarbo-
nate inserts; Corning Incorporated, Corning, NY, USA)
were coated either with collagen or 10% Matrigel
® (BD
Biosciences, Heidelberg, Germany) in DMEM and sub-
sequently added to 24-wells containing DMEM (nega-
tive control) or DMEM/10% FCS/50 ng/ml
recombinant human HGF (NatuTec, Frankfurt, Ger-
many) as a chemoattractant. Cells (1 × 10
5)w e r e
seeded in DMEM in the inside compartments and
allowed to migrate for 16 h (HUH7) or 72 h (HepG2)
i nt h ep r e s e n c eo ra b s e n c eo f1μg/ml recombinant
human IGFBP3 (R&D systems). Afterwards, the inserts
were stained with crystal violet solution. Cells from the
upper side of the insert were removed by using cotton
swabs. Cells attached to the bottom side of the insert
were photographed using a Zeiss Axiovert 25 micro-
scope and a Canon 450D camera. For each sample,
eight pictures were taken, and the number of cells was
calculated by using ImageJ (National Institute of
Health, Bethesda, MD, USA) and the Particle Counter
plugin. Data for three independent experiments were
analyzed using GraphPad Prism Version 3.0 (GraphPad
Software, La Jolla, CA, USA).
Statistical analysis
The data are presented either as dot plots or bar graphs,
indicating the mean ± SEM. The statistical analyses and
Kaplan Meier calculations were performed with Graph-
Pad Prism Version 3.0 using Student’su n p a i r e dt-test,
Mantel-Cox test, Mann-Whitney-U test, Spearman’s
rank correlation, one-way ANOVA and Dunnett’s test. P
< 0.05 was considered to be significant.
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